Frontier Pharma: Ophthalmology Therapeutics Market Outlook by Product Overview, Application and Regions by 2022

This report identifies the Frontier Pharma: Ophthalmology Therapeutics market size for the years 2012-2017, and forecast of the same till the year 2022. It also highlights the market drivers, restraints, growth indicators, challenges and other key aspects with respect to the Frontier Pharma: Ophthalmology Therapeutics market.

The ophthalmologic therapy area encompasses a wide range of disorders affecting the eye and its supporting structures. These include glaucoma, age-related macular degeneration (AMD), diabetic retinopathy (DR), diabetic macular edema (DME) and dry eye syndrome (DES). The therapy area is characterized by vast unmet need, as patients have few treatment options and poor outcomes.

To Get Sample Copy of Report visit @ https://www.reportsmonitor.com/request-sample/?post=460456 

This report assesses first-in-class innovation in the ophthalmology pipeline, highlighting key trends in the distribution of these products. In-depth analysis reveals that the level of innovation within the therapy area pipeline is high, with strong potential for drugs to address unmet needs and be commercially lucrative. First-in-class drugs account for 38% of products with a disclosed molecular target, acting on 151 unique molecular targets, which is indicative of the approach being taken in the field.                                                                   

In the past the ophthalmological disorders therapy area has suffered from a lack of full understanding of the pathophysiology and underlying mechanisms of the diseases. However, as this knowledge has improved vastly in recent years, potential targets have been identified for treatment. As well as the main disorders previously mentioned, there is also interest in developing treatments for indications such as allergic conjunctivitis and retinitis pigmentosa. The approval of a gene therapy for retinitis pigmentosa is indicative of this progress, and represents the first gene therapy approved for an inherited condition by the FDA.

The pipeline is varied in terms of molecular targets and molecule types. Products acting on the immune system and neurotransmitter signaling are the most prevalent, but no single target dominates by any clear margin. There are a total of 194 first-in class pipeline products in development for ophthalmologic indications – 38% of the 512 pipeline products for which there is a disclosed molecular target. Encompassing gene therapies, slowing of the visual cycle and antisense therapies, the pipeline appears robust and has huge potential to strengthen treatment options for ophthalmological disorders.  

To enquiry of report visit @ https://www.reportsmonitor.com/make-enquiry/?post=460456          

Scope 

– The pipeline is large, with 865 products in active development. Does current pipeline innovation hold the potential to affect the future ophthalmology market?

– There are 194 first-in-class products in the ophthalmologic disorder pipeline. Which of these possess the greatest potential to improve disease outcome and be commercially successful, based on their target?

– Analysis of strategic consolidations and deals revealed a high level of activity in recent years for licensing agreements, but a low level of co-development. How do deal frequency and value compare between molecular targets and molecule types, and which first-in-class targets have not yet been involved in deals? 

Check Discount on this report @ https://www.reportsmonitor.com/check-discount/?post=460456

We at Reports Monitor provide a comprehensive analysis by providing in-depth reports of the various market verticals. Our Mission is to provide a detailed analysis of the vast markets worldwide, backed by rich data. Decision makers can now rely on our well-defined data gathering methods to get the correct and accurate market forecasting along with detailed analysis.
Contact Us
Jay Matthews
Email: sales@reportsmonitor.com

Leave a Reply

Your email address will not be published. Required fields are marked *